Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Somatropin - Novo Nordisk

Drug Profile

Somatropin - Novo Nordisk

Alternative Names: NN-1610; NN-220; Norditropin; Norditropin cartridge; Norditropin FlexPro; Norditropin NordiFlex; Norditropin NordiLet; Norditropin NordiPen; Norditropin S; Norditropin SimpleXx; Somatotropin - Novo Nordisk

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novo Nordisk
  • Class Growth hormones; Hormonal replacements; Obesity therapies
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short stature; Female infertility; Somatotropin deficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dwarfism; Growth disorders; Short stature; Somatotropin deficiency
  • Discontinued Female infertility; Fracture; Nutrition disorders

Most Recent Events

  • 01 Apr 2016 Final adverse events and efficacy data from a phase III trial in Idiopathic short stature presented at the The 98th Annual Meeting of the Endocrine Society (ENDO-2016)
  • 26 Jan 2015 The US FDA approves Norditropin® FlexPro® (somatropin [rDNA origin] injection, 30 mg/3.0ml) for treatment of Somatotropin deficiency in USA
  • 05 Feb 2014 Novo Nordisk completes enrolment in its phase III trial for Short stature (idiopathic, in children) in South Korea (NCT01778023)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top